Sorafenib (brand name Nexavar) / Twist Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱
Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 RAF → MEK → ERK (MAPK) ↓ (primary) ↔ / ↓ (proliferating cells) R/G Reduced proliferative signaling Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2 VEGFR / PDGFR (angiogenesis) ↓ tumor vascularization ↓ endothelial proliferation R/G Anti-angiogenic effect Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3 Intrinsic apoptosis (Mcl-1↓, caspases↑) ↑ ↔ / ↑ (dose-dependent) R/G Mitochondrial apoptosis Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4 ROS ↑ (dose-dependent) ↔ / ↑ (high exposure) P/R Oxidative stress contribution Redox stress may contribute to cytotoxicity and resistance mechanisms.
5 Ferroptosis ↑ (context-dependent) ↔ R/G Lipid peroxidation vulnerability Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6 PI3K/AKT/mTOR ↓ (secondary; model-dependent) ↔ R/G Reduced survival signaling Often compensatory pathway in resistance; combination target in trials.
7 HIF-1α ↓ (anti-angiogenic coupling) ↔ G Reduced hypoxia signaling Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8 NRF2 ↑ (resistance-associated; context-dependent) ↔ R/G Adaptive antioxidant response NRF2 upregulation linked to sorafenib resistance in HCC.
9 Ca²⁺ signaling ↔ (stress-related) ↔ P/R Not primary axis Secondary to mitochondrial stress; not direct target.
10 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Resistance + tolerability limits Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)
Twist, Twist: Click to Expand ⟱
Source:
Type: transcription factor
Twist, the basic helix-loop-helix transcription factor, is involved in the process of epithelial to mesenchymal transitions (EMTs), which play an essential role in cancer metastasis. Overexpression of Twist or its promoter methylation is a common scenario in metastatic carcinomas. Twist is a key transcription factor for Epithelial-mesenchymal transition (EMT).
Twist-1 overexpression was shown, recently, to be a factor of poor prognosis in melanomas Many studies use “TWIST” and “TWIST1” interchangeably (with TWIST1 being the canonical factor in humans.

Twist plays key roles in embryonic development and has been implicated in cancer progression, particularly through promoting epithelial-mesenchymal transition (EMT), invasion, and metastasis. TWIST1 directly represses epithelial markers (e.g., E-cadherin) while upregulating mesenchymal markers (e.g., N-cadherin, vimentin).

Twist is most often upregulated in cancer cells compared to normal cells across multiple tumor types.
– High Twist expression is consistently associated with aggressive clinical features, including increased invasiveness, metastasis, and reduced overall survival.
Scientific Papers found: Click to Expand⟱
6915- FIS,  SRF,    Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
- in-vitro, Melanoma, NA
EMT↓, TumCP↓, PI3K↓, eff↑, N-cadherin↓, Vim↓, Fibronectin↓, E-cadherin↑, Snail↓, Twist↓, Slug↓, Zeb1↓, MMP2↓, MMP9↓, TumCI↓, TumMeta↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   PI3K↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   Fibronectin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Twist, Twist
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:16  Target#:421  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page